News
EngagedMD raises US$11m in funding to make fertility care more accessible
The company’s software integrates patient education and engagement into existing clinical workflows to reduce clinical burden
A Washington, DC-based technology company has raised US$11m in funding to make fertility care more accessible.
The funding round, led by the venture capital firm MonCap, will help EngagedMD to expand its global presence and expansion into other healthcare verticals.
As part of the investment, EngagedMD has also welcomed Jonathan Sockol, managing partner of MonCap, to the company’s board.
The company currently supports more than half of all patients in the US, UK, and Canada through its cloud-based SaaS platform that empowers patients and providers to collaborate and make informed decisions.
Its software integrates patient education and engagement into existing clinical workflows to reduce clinical burden and improve patient experiences and outcomes.
The company says clinics using EngagedMD save up to two hours of manual time per patient, allowing them to provide better and more accessible care to more patients.
A number of medical journals have also clinically validated the firm’s impact on patient experience, noting benefits such as enhanced knowledge, control over decision making, and overall satisfaction scores.
“We are excited to partner with MonCap on EngagedMD’s next chapter of growth,” said Taylor Stein, co-founder and co-CEO of EngagedMD.
“MonCap has a proven track record of adding value and their expertise will help us further our mission of making patients’ and providers’ lives easier.
His co-founder, Jeff Issner, said the company would use the funds to continue developing products that support providers and patients navigating a complex care journey.
“We also look forward to expanding our platform into other specialties in our relentless journey to make healthcare more efficient and effective,” he added.
MonCap’s Sockol said: “EngagedMD has already positively impacted the lives of over one and a half million patients. We are proud to back this team in making better care more accessible to even more patients across healthcare.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Hormonal health3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Diagnosis2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now







1 Comment